{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+1&page=4", "query": { "intervention": "Combination Agent 1", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 4092, "total_pages": 410, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+1&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+1&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T19:35:23.948Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000882", "title": "Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Delavirdine mesylate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-29", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 30, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000882" }, { "nct_id": "NCT03501979", "title": "Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Leptomeningeal Disease" ], "interventions": [ { "name": "Tucatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2019-02-20", "completion_date": "2021-06-22", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03501979" }, { "nct_id": "NCT06039579", "title": "Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4004280", "type": "DRUG" }, { "name": "VH4011499", "type": "DRUG" }, { "name": "VH4004280 Matching Placebo", "type": "DRUG" }, { "name": "VH4011499 Matching Placebo", "type": "DRUG" }, { "name": "Antiretroviral therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2023-10-25", "completion_date": "2024-06-24", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 3, "location_summary": "Bakersfield, California • DeLand, Florida • Newark, New Jersey", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06039579" }, { "nct_id": "NCT02736123", "title": "Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Nivolumab - Arm A", "type": "DRUG" }, { "name": "Nivolumab + Ipilimumab - Arm B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-10", "completion_date": "2017-02-09", "has_results": false, "last_update_posted_date": "2017-09-20", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02736123" }, { "nct_id": "NCT05076942", "title": "Groningen International Study on Sentinel Nodes in Vulvar Cancer-III", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vulvar Cancer", "Sentinel Lymph Node", "Lymph Node Metastases" ], "interventions": [ { "name": "Radiotherapy combined with cisplatin", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University Medical Center Groningen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 157, "start_date": "2021-01-01", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 21, "location_summary": "Orange, California • Miami Beach, Florida • Springfield, Massachusetts + 18 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Traverse City", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05076942" }, { "nct_id": "NCT05719441", "title": "A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute HIV Infection" ], "interventions": [ { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "PGT121.414.LS", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "ART", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 48, "start_date": "2024-08-19", "completion_date": "2029-06-18", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05719441" }, { "nct_id": "NCT05181683", "title": "COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Chronic Stable Illness" ], "interventions": [ { "name": "Casirivimab+Imdevimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 45, "start_date": "2022-01-07", "completion_date": "2022-06-03", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 2, "location_summary": "Miami, Florida • Winter Park, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05181683" }, { "nct_id": "NCT06209359", "title": "Mechanisms of Diuretic Resistance in Heart Failure, Aim 3", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Heart Failure", "Diuretic Resistance" ], "interventions": [ { "name": "Ammonium Chloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-07-24", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06209359" }, { "nct_id": "NCT03996473", "title": "Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY 88-8223)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2020-03-06", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 1, "location_summary": "San Marcos, California", "locations": [ { "city": "San Marcos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03996473" }, { "nct_id": "NCT04569747", "title": "A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Invasive Carcinoma of the Breast", "Breast Cancer", "Node Negative Breast Cancer", "Micrometastasis Breast Cancer", "Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "Pertuzumab+TRASTUZUMAB", "type": "COMBINATION_PRODUCT" }, { "name": "ADJUVANT ENDOCRINE THERAPY", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 393, "start_date": "2021-01-11", "completion_date": "2032-09-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-13T19:35:23.948Z", "location_count": 32, "location_summary": "Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more", "locations": [ { "city": "Stamford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04569747" } ] }